ArticleThe oncologist2021

A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors.

Yuxiang Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.